PTC Therapeutics (Nasdaq: PTCT) saw its shares decline 11.7% to $9.64, after it revealed that it has entered into an asset purchase agreement with privately-held Marathon Pharmaceuticals to acquire all rights to Emflaza (deflazacort).
In February this year, Emflaza became the first treatment approved in the USA for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. Emflaza aligns with PTC's mission to bring therapies to patients who have rare diseases with limited or no treatment options, stated the company, whose own DMD drug Translarna (ataluren) was given conditional approval in Europe in 2014, but is still awaiting clearance in the USA.
Hefty price tag previously criticized
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze